Drug intelligence / Profile preview

NVP-1603-1

Development stage: Unknown
Lead developer: Navipharm
Modality: Small Molecules

Overview

NVP-1603-1 is a small molecule drug developed by Navipharm for the treatment of pain and potentially other nervous system diseases. It is part of a series of compounds known as "NVP 1603" that have been under research for their therapeutic applications in the nervous system. The specific mechanism of action and molecular targets have not been disclosed publicly. The drug has reached Phase 1 clinical development, with at least one trial initiated to assess pharmacokinetics and safety/tolerability in healthy volunteers[1][2].

Beyond the preview

Go deeper on NVP-1603-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVP-1603-1.

Explore the full profile